Disc Medicine (IRON) reported a 2024 loss Thursday of $3.96 per share, wider than a loss of $3.42 a year earlier.
Analysts polled by FactSet expected a loss of $4.13.
As expected, no revenue was reported.
As of Dec. 31, the company had $489.9 million in cash, cash equivalents and marketable securities. Combined with $243.3 million from an underwritten public offering, the company said it expects this will fund its operations into 2028.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.